Filtros de búsqueda

Lista de obras de Miguel Martin

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol.

artículo científico

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

artículo científico publicado en 2015

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

artículo científico publicado en 2011

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study

artículo científico publicado en 2018

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer ⬇️

artículo científico publicado el 15 de agosto de 2013

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome

artículo científico publicado en 2011

A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients

artículo científico publicado en 2013

A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer

artículo científico publicado en 2007

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

scientific article published on 20 September 2020

Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer

scientific article published on 12 August 2020

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

artículo científico publicado en 2012

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

artículo científico publicado en 2012

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization

artículo científico publicado en 2011

BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.

artículo científico publicado en 2010

Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.

artículo científico publicado en 2007

Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.

artículo científico publicado en 2013

Bevacizumab treatment for advanced breast cancer

artículo científico publicado en 2011

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

scientific article published on 16 September 2019

Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid

artículo científico publicado en 2012

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

artículo científico publicado en 2009

Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.

artículo científico publicado en 2010

Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

artículo científico publicado en 2012

Capecitabine plus docetaxel combination therapy

artículo científico publicado en 2005

Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans.

artículo científico publicado en 2011

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

artículo científico publicado en 2014

Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis

artículo científico publicado en 2009

Circulating tumor cells in solid tumor in metastatic and localized stages

artículo científico publicado en 2009

Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients

artículo científico publicado en 2006

Circulating tumour cells in locally advanced breast cancer

scientific article published on 01 August 2009

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.

artículo científico publicado en 2014

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

artículo científico publicado en 2013

Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

artículo científico publicado en 2018

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.

artículo científico publicado en 2013

Denosumab for the treatment of bone metastases in advanced breast cancer.

artículo científico

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.

artículo científico publicado en 2008

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

artículo científico publicado en 2003

Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer.

artículo científico publicado en 2006

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

scientific article published on 24 January 2012

Docetaxel-related side effects and their management

artículo científico publicado en 2008

Docetaxel-related side effects and their management

artículo científico publicado en 2009

Elementary, My Dear Watson

artículo científico publicado en 2007

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

artículo científico publicado en 2008

Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

artículo científico publicado en 2010

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

artículo científico publicado en 2011

Exercise and cancer: a position statement from the Spanish Society of Medical Oncology

artículo científico publicado en 2020

Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy

artículo científico publicado en 2001

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

artículo científico publicado en 2013

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study

artículo científico publicado en 2013

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

scientific article published on 01 March 2007

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis

artículo científico publicado en 2014

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

artículo científico publicado en 2015

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study

scientific article published on 28 June 2013

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses

artículo científico publicado en 2014

Incidence-based cost-of-illness model for metastatic breast cancer in the United States.

artículo científico publicado en 2012

Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM)

scientific article published on 06 July 2006

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

artículo científico publicado en 2012

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

artículo científico publicado en 2015

Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.

artículo científico publicado en 2005

Maintenance therapy in breast cancer—many questions remain ⬇️

artículo científico publicado el 28 de mayo de 2013

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

artículo científico publicado en 2010

Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore.

artículo científico publicado en 2014

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

artículo científico publicado en 2011

Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

artículo científico publicado en 2012

Moving forward with capecitabine: a glimpse of the future

artículo científico publicado en 2002

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

artículo científico publicado en 2010

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

artículo científico publicado en 2004

Neratinib (HKI-272) in the treatment of breast cancer.

artículo científico

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

artículo científico publicado en 2013

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

article

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

artículo científico publicado en 2012

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

artículo científico publicado en 2013

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

artículo científico publicado en 2015

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

scientific article published on 30 July 2018

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

artículo científico publicado en 2018

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

artículo científico publicado en 2018

Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.

artículo científico publicado en 2010

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

artículo científico publicado en 2007

Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.

artículo científico publicado en 2004

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study

scientific article published on 31 May 2019

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

artículo científico publicado en 2011

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

artículo científico publicado en 2010

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

artículo científico publicado en 2011

Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.

artículo científico publicado en 2015

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

artículo científico publicado en 2019

Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.

artículo científico publicado en 2011

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer

scientific article published on 15 October 2019

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

artículo científico publicado en 2020

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

artículo científico publicado en 2014

Prognostic and predictive factors and genetic analysis of early breast cancer.

artículo científico publicado en 2009

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

artículo científico publicado en 2019

Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.

artículo científico publicado en 2009

Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer

artículo científico publicado en 2010

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

artículo científico publicado en 2010

Retrospective subset analyses in early breast cancer revisited

scientific article published on 12 October 2009

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients.

artículo científico

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

artículo científico publicado en 2014

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study

artículo científico publicado en 2014

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis

artículo científico publicado en 2015

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

scientific article published on 27 December 2019

The evolving landscape of protein kinases in breast cancer: clinical implications.

artículo científico

The global breast cancer burden: variations in epidemiology and survival.

artículo científico publicado en 2005

The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.

artículo científico publicado en 2008

Time-to-progression in breast cancer: a stratification model for clinical trials.

artículo científico publicado en 2007

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

artículo científico

Trans-generational radiation-induced chromosomal instability in the female enhances the action of chemical mutagens.

artículo científico publicado en 2007

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

artículo científico publicado en 2005

Understanding the value of antiangiogenic therapy in metastatic breast cancer ⬇️

artículo científico publicado el 1 de abril de 2011

Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.

artículo científico publicado en 2003

Zooming in on the schedule of bone-modifying drugs.

artículo científico publicado en 2013

[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project]

scientific article published on 01 January 2004

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda